BSX · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 43 · Surprise 32 · From source text

Net sales increased 1.5% to $5.138 billion in the third quarter of 2026 and 6.7% to $15.784 billion in the first nine months, with nine-month organic growth of 5.8%. Nine-month Cardiovascular sales grew 7.8% to $10.532 billion, while MedSurg sales grew 4.7% to $5.252 billion; reported growth was 13.1% for Neuromodulation in the quarter and 14.3% for the first nine months. Third-quarter growth was led by Cardiovascular’s coronary therapies, including AGENT, but was offset by manufacturing and order-fulfillment disruption from the cybersecurity incident, Electrophysiology competition, and slower WATCHMAN procedures. Nine-month Cardiovascular growth was led by AGENT and Farapulse, while Endoscopy grew 5.3% and Urology declined 0.1%, with China volume-based procurement and operational disruption weighing on those businesses.

Key facts

• Third-quarter 2026 reported net sales were $5,138 million, up 1.5% from $5,065 million in the third quarter of 2025. source
• Nine-month 2026 reported net sales were $15,784 million, up 6.7% from $14,788 million in the prior-year period. source
• Third-quarter 2026 net sales grew 1.5% on a reported, operational, and organic basis; foreign currency had no impact. source
• Nine-month 2026 net sales grew 6.7% reported, 5.8% operationally, and 5.8% organically; foreign currency reduced growth by 0.9 percentage points. source
• Third-quarter 2026 revenue growth was driven primarily by ICVT innovation and commercial execution, offset by cybersecurity-related manufacturing and order-fulfillment disruptions, increased Electrophysiology competition, and slower LAAC market growth impacting WATCHMAN procedures. source
• Nine-month 2026 revenue growth was driven primarily by ICVT and Electrophysiology, offset by increased Electrophysiology competition and deceleration in the LAAC market impacting WATCHMAN procedures. source

Impact estimates